Ernexa Therapeutics Inc. Logo

Ernexa Therapeutics Inc.

Biopharmaceutical company developing cell therapies for cancer and autoimmune diseases.

ERNA | US

Overview

Corporate Details

ISIN(s):
US6294106066 (+1 more)
LEI:
Country:
United States of America
Address:
1035 CAMBRIDGE STREET, 2141 CAMBRIDGE

Description

Ernexa Therapeutics Inc. is a biopharmaceutical company developing cell therapies for advanced cancer and autoimmune diseases. The company's core technology platform engineers induced pluripotent stem cells (iPSCs) and differentiates them into induced mesenchymal stem cells (iMSCs). These engineered iMSCs are designed as scalable, off-the-shelf treatments that leverage the natural ability of MSCs to home to sites of tumors or inflammation. Once at the target site, the cells deliver therapeutic payloads, such as cytokines, to modulate the immune system. The company's lead candidate, ERNA-101, is being developed for the treatment of ovarian cancer. Its pipeline also includes ERNA-201, a cell therapy designed to target inflammation in autoimmune diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-07 17:30
10-Q
English 1.3 MB
2025-08-18 18:05 English 8.9 KB
2025-08-13 18:31
10-Q
English 1.2 MB
2025-07-07 22:00 English 7.5 KB
2025-07-07 18:39
8-K
English 72.8 KB
2025-06-20 02:15 English 5.4 KB
2025-06-18 18:57
424B3
English 36.0 KB
2025-06-16 18:05 English 6.8 KB
2025-06-16 11:36 English 58.0 KB
2025-06-12 18:37
8-K
English 73.5 KB
2025-06-11 22:39 English 10.8 KB
2025-06-11 22:34
OWNERSHIP DOCUMENT
English 7.4 KB
2025-06-11 18:35
S-8
English 83.8 KB
2025-06-11 18:30
S-3
English 105.3 KB
2025-06-09 18:30
8-K
English 70.0 KB

Automate Your Workflow. Get a real-time feed of all Ernexa Therapeutics Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Ernexa Therapeutics Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Ernexa Therapeutics Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Access Bio, Inc. Logo
Develops and manufactures in vitro diagnostic solutions for infectious diseases.
United States of America
950130
ACHIEVE LIFE SCIENCES, INC. Logo
A late-stage pharmaceutical company developing a treatment for nicotine dependence.
United States of America
ACHV
AC Immune SA Logo
Biopharmaceutical firm developing precision medicine for neurodegenerative diseases.
United States of America
ACIU
Aclaris Therapeutics, Inc. Logo
Clinical-stage biopharmaceutical company developing drugs for immuno-inflammatory diseases.
United States of America
ACRS
Acrivon Therapeutics, Inc. Logo
Clinical-stage biopharma using proteomics to develop precision oncology therapies.
United States of America
ACRV
Acticor Biotech Logo
Develops treatments for thrombotic diseases, focusing on acute ischemic stroke.
France
ALACT
Actinium Pharmaceuticals, Inc. Logo
Clinical-stage company developing targeted radiotherapies for difficult-to-treat cancers.
United States of America
ATNM
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing therapies for cancers with high unmet needs.
United States of America
ACTU
AcuCort AB Logo
Develops user-friendly drug formulations for severe and acute allergic reactions.
Sweden
ACUC
Acumen Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing targeted therapies for Alzheimer's disease.
United States of America
ABOS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.